News | January 26, 2024
Astec LifeSciences posts Q3 FY24 consolidated loss at Rs. 24.33 Cr
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
To enable company to be future-ready by tapping potential in CDMO space
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)